These NGS panels target genes that are associated with multiple hematological conditions, e.g., DNMT3A, TET2, ASXL1, and genes that are implicated in the pathogenesis of specific hematological disorders, e.g., JAK2 for myeloproliferative neoplasms (MPN). Here, ASXL1 is linked to myeloproliferative disorder.